度他雄胺治疗良性前列腺增生的预算影响分析

Budget Impact Analysis on Using Dutasteride for the Treatment of Benign Prostatic Hyperplasia

目的:从全国城镇基本医疗保险的角度出发,评价将度他雄胺纳入"国家医保药品目录"对医保支付方预算的影响,为医疗保险部门提供决策依据。方法:通过构建预算影响分析模型,对目标人群、当前和未来可能的治疗方案组合、药品费用和疾病相关医疗费用进行估计,把度他雄胺纳入"国家医保药品目录"的情境和度他雄胺不纳入的情境相比,分析未来5年(2014—2018年)总预算的变化。结果:两种情境相比,未来5年内医保支付的差值分别为:-232万元、-837万元、-1 930万元、-2 867万元和-3 977万元。结论:将度他雄胺纳入"国家医保药品目录"可能会带来医保总预算的节约。

Objective:To evaluate the budge impact of listing Dutasteride in'National reimbursement drug list(NRDL)' from therespective of National Urban Basic Medical Insurance so as to provide evidence for medical insurance decision maker.Methods:Abudget impact analysis model was constructed to estimate the target population, the current and future treatment combinations, costs ofdrugs and diseaserelated healthcare. The potential scenario(Dutasteride was listed in NRDL) was compared to the reference scenario(Dutasteride was not listed in NRDL). The budget changes in the following 5 years(2014—2018) were analyzed.Results:Compared tothe reference scenario, the net saving in the following 5 years were estimated as2.32 million,8.37 million,19.30 million,28.67 million and39.77 million respectively. Conclusion: Listing Dutesteride in NRDL could lead to general budget saving ofmedical insurance.